We were delighted to talk with Dr Michael R. McClung (Oregon Osteoporosis Center, Portland, OR, USA) around the current unmet needs and standard of care for osteoporosis and the therapeutic targets currently being investigated that could lead to new drug approvals.
‘Can we expect new chemical entities for the management of osteoporosis in the coming years‘ was presented at WCO IOF-ESCEO 2022, 24-26 March, 2022
Questions
- What are the current unmet needs in the management of osteoporosis? (0:16)
- What would the “ideal” osteoporosis drug look like? (1:31)
- Are there therapeutic targets that appear particularly promising? (2:22)
- Which of these mechanisms is most likely to lead to new drug approvals in the coming years? (3:34)
- What should be done while we await these new treatments? (4:30)
Disclosures: Michael McClung discloses consulting for Amgen and Myovant; serving on advisory boards for Amgen; receiving honoraria from Amgen; and participating in speaker’s bureaus for Amgen and Alexion.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the WCO IOF-ESCEO annual meeting 2022.
